• Oncotelic Therapeutics disclosed open-market purchases by Trieu Vuong, chairman and CEO.
• Vuong acquired 255,000 common shares at USD 0.05 each.
• Directly held common stock rose to 93,884,319 shares following the purchases.
• Report also lists indirect holdings of 16,780,384 shares via Autotelic Inc. plus 6,872,529 shares held by his spouse.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029997), on June 24, 2026, and is solely responsible for the information contained therein.